Meta-analysis of randomized controlled trials for the association of incretins with fractures risk in patients with type 2 diabetes
10.3760/cma.j.cn311282-20200226-00102
- VernacularTitle:基于随机对照研究探讨肠促胰素对骨折影响的 meta分析
- Author:
Jie MA
1
;
Jing PENG
;
Yingzhe JIANG
;
Xiaofu CAO
;
Cheng JI
;
Lijun WANG
;
Weihong GE
Author Information
1. 北京大学深圳医院药学部 518036
- From:
Chinese Journal of Endocrinology and Metabolism
2020;36(10):844-854
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To conduct a meta-analysis of clinical data to investigate the relationship between incretins and fracture in order to provide individualized hypoglycemic agents for type 2 diabetic patients with osteoporosis.Methods:PubMed, Embase, Web of Science, and Cochrane databases were searched up to January 1, 2018 for randomized controlled trials(RCTs)and the relationship between incretins and fracture was explored by meta-analysis.Results:The meta-analysis showed that the use of incretin was not associated with fracture risk compared with placebo or other positive hypoglycemic agents( OR 0.972, 95% CI 0.876-1.079). But in the subgroup analysis, 100 mg/d sitagliptin( OR 0.495, 95% CI 0.304-0.806)or 1.8 mg/d liraglutide( OR 0.621, 95% CI 0.413-0.933)reduced fracture risk. Conclusions:Meta-analysis shows no increase in the incidence of fracture events after the use of incretin. 100 mg/d sitagliptin or 1.8 mg/d liraglutide may exert protective effects on bone metabolism. However, the included data are from the reports of fracture adverse reactions in RCT studies, and large-scale clinical studies are needed to confirm these findings.
